| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Departments of 1 Oncology, Cancer Research Centre, and 2 Surgery, Queen’s University Belfast, Belfast, Northern Ireland
To elucidate mechanisms of resistance to chemotherapies currently used in the first-line treatment of advanced colorectal cancer, we have developed a panel of HCT116 p53 wild-type (p53+/+) and null (p53-/-) isogenic colorectal cancer cell lines resistant to the antimetabolite 5-fluorouracil (5-FU), topoisomerase I inhibitor irinotecan (CPT-11), and DNA-damaging agent oxaliplatin. These cell lines were generated by repeated exposure to stepwise increasing concentrations of each drug over a period of several months. We have demonstrated a significant decrease in sensitivity to 5-FU, CPT-11, and oxaliplatin in each respective resistant cell line relative to the parental line as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis, with increases in IC50 (72 h) concentrations ranging from 3- to 65-fold. Using flow cytometry, we have also demonstrated compromised apoptosis and cell cycle arrest in 5-FU-, oxaliplatin-, and CPT-11-resistant cell lines compared with the parental lines after exposure to each drug. In addition, we found that resistance to 5-FU and oxaliplatin was higher in parental p53-/- cells compared with parental p53+/+ cells, with an 
5-fold increase in IC50 (72 h) for each drug. In contrast, the IC50 (72 h) doses for CPT-11 were identical in the p53 wild-type and null cell lines. Furthermore, apoptosis after treatment with 5-FU and oxaliplatin, but not CPT-11, was significantly reduced in parental p53-/- cells compared with parental p53+/+ cells. These data suggest that p53 may be an important determinant of sensitivity to 5-FU and oxaliplatin but not CPT-11. Using semiquantitative reverse transcription-PCR, we have demonstrated down-regulation of thymidine phosphorylase mRNA in both p53+/+ and p53-/- 5-FU-resistant cells, suggesting that decreased production of 5-FU active metabolites may be an important resistance mechanism in these lines. In oxaliplatin-resistant cells, we noted increased mRNA levels of the nucleotide excision repair gene ERCC1 and ATP-binding cassette transporter breast cancer resistance protein. In CPT-11-resistant cells, we found reduced mRNA levels of carboxylesterase, the enzyme responsible for converting CPT-11 to its active metabolite SN-38, and topoisomerase I, the SN-38 target enzyme. In addition, we noted overexpression of breast cancer resistance protein in the CPT-11-resistant lines. These cell lines are ideal tools with which to identify novel determinants of drug resistance in both the presence and absence of wild-type p53.
This article has been cited by other articles:
|
|
 |
|
  S. Nemoto, M. Nakamura, Y. Osawa, S. Kono, Y. Itoh, Y. Okano, T. Murate, A. Hara, H. Ueda, Y. Nozawa, et al. Sphingosine Kinase Isoforms Regulate Oxaliplatin Sensitivity of Human Colon Cancer Cells through Ceramide Accumulation and Akt Activation J. Biol. Chem., April 17, 2009; 284(16): 10422 - 10432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Wilson, W. Fazzone, M. J. LaBonte, H.-J. Lenz, and R. D. Ladner Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage Nucleic Acids Res., January 1, 2009; 37(1): 78 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lee, A. Belkhiri, A. C. Lockhart, N. Merchant, H. Glaeser, E. I. Harris, M. K. Washington, E. M. Brunt, A. Zaika, R. B. Kim, et al. Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer Cancer Res., December 15, 2008; 68(24): 10315 - 10323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Okumura, S. Huang, and F. A. Sinicrope Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737 Clin. Cancer Res., December 15, 2008; 14(24): 8132 - 8142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Allen, V. M. Coyle, P. V. Jithesh, I. Proutski, L. Stevenson, C. Fenning, D. B. Longley, R. H. Wilson, M. Gordon, H.-J. Lenz, et al. Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models Clin. Cancer Res., October 15, 2008; 14(20): 6647 - 6655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Sharma and T. A.D. Smith Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in 18F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport J. Nucl. Med., August 1, 2008; 49(8): 1386 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Mason, S. McFarlane, P. G. Johnston, P. Crowe, P. J. Erwin, M. M. Domostoj, F. C. Campbell, S. Manaviazar, K. J. Hale, and M. El-Tanani Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation Mol. Cancer Ther., March 1, 2008; 7(3): 548 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-X. Sun, M.-S. Dai, and H. Lu 5-Fluorouracil Activation of p53 Involves an MDM2-Ribosomal Protein Interaction J. Biol. Chem., March 16, 2007; 282(11): 8052 - 8059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Allen, E. G. McLean, J. Boyer, A. McCulla, P. M. Wilson, V. Coyle, D. B. Longley, R. A. Casero Jr., and P. G. Johnston The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Smakman, D. J.M. van den Wollenberg, S. G. Elias, T. Sasazuki, S. Shirasawa, R. C. Hoeben, I. H.M. Borel Rinkes, and O. Kranenburg KRASD13 Promotes Apoptosis of Human Colorectal Tumor Cells by ReovirusT3D and Oxaliplatin but not by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Cancer Res., May 15, 2006; 66(10): 5403 - 5408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Boyer, W. L. Allen, E. G. McLean, P. M. Wilson, A. McCulla, S. Moore, D. B. Longley, C. Caldas, and P. G. Johnston Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res., March 1, 2006; 66(5): 2765 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Galligan, D. B. Longley, M. McEwan, T. R. Wilson, K. McLaughlin, and P. G. Johnston Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP Mol. Cancer Ther., December 1, 2005; 4(12): 2026 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
